Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ARTBIO Inc.
This is a single site, open label, non-randomized, non-controlled intervention study with an initial microdosing run-in part (phase 0), followed by a conventional dose-escalation phase 1 part.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
ECOG performance status of 0 to 2
Life expectancy \>6 months
Histological, pathological, and/or cytological confirmation of prostate cancer
Metastatic castration resistant prostate cancer
Failure of conventional treatment or such treatment not available/accepted by patient
PSMA avid mCRPC lesions confirmed by PSMA PET/CT
Adequate hematopoietic, kidney and liver function
You may not be if
Concurrent or other cancer diagnosis last two years, except for carcinoma in situ
Concomitant diseases not compatible for radioactive therapy
Previous PSMA-targeted radioligand therapy
Concurrent serious (as determined by the Principal Investigator) medical conditions
